This is an old revision of this page, as edited by Edgar181 (talk | contribs) at 18:03, 3 November 2011 (chembox tweaks). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 18:03, 3 November 2011 by Edgar181 (talk | contribs) (chembox tweaks)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) | |
| Names | |
|---|---|
| IUPAC name 4-(4-{3-propoxy}-3,5-difluorophenyl)benzonitrile | |
| Identifiers | |
| CAS Number | |
| 3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
InChI
| |
SMILES
| |
| Properties | |
| Chemical formula | C22H25F2N3O |
| Molar mass | 385.4502 g mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).
 N verify (what is ?)
Infobox references
| |
A-423,579 is one of a range of histamine antagonists developed by Abbott Laboratories which are selective for the H3 subtype, and have stimulant and anorectic effects in animal studies making them potentially useful treatments for obesity. A-423,579 has improved characteristics over earlier drugs in the series with both high efficacy and low toxicity in studies on mice, and is currently in clinical development.
References
- Hancock AA, Diehl MS, Faghih R, Bush EN, Krueger KM, Krishna G, Miller TR, Wilcox DM, Nguyen P, Pratt JK, Cowart MD, Esbenshade TA, Jacobson PB (2004). "In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists". Basic Clin. Pharmacol. Toxicol. 95 (3): 144–52. doi:10.1111/j.1742-7843.2004.950307.x. PMID 15447739. Retrieved 2008-11-25.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - Hancock AA, Diehl MS, Fey TA, Bush EN, Faghih R, Miller TR, Krueger KM, Pratt JK, Cowart MD, Dickinson RW, Shapiro R, Knourek-Segel VE, Droz BA, McDowell CA, Krishna G, Brune ME, Esbenshade TA, Jacobson PB (2005). "Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy". Inflamm. Res. 54 Suppl 1: S27–9. doi:10.1007/s00011-004-0412-z. PMID 15928821.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link)
 | This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it. |